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Background: The aim of this study was to analyse which factors predict the real-world macro-/microvascular
event, hospitalisation and death risk in patients with type 2 diabetes mellitus. Furthermore, we aimed to investigate
whether there exists both an under- and over-treatment risk of these patients.
Methods: We used a German claims/clinical data set covering the years 2010–12. Diabetes-related events were defined
as (1) macro-, (2) microvascular events leading to inpatient hospitalisation, (3) other hospitalisations with type 2 diabetes
mellitus as main diagnosis, (4) all-cause death and (5) a composite outcome including all event categories 1–4. Factors
associated with event risk were analysed by a Kaplan-Meier curve analysis and by multivariable Cox regression models.
Results: 229,042 patients with type 2 diabetes mellitus (mean age 70.2 years; mean CCI 6.03) were included. Among
factors that increased the event risk were patients’ age, male gender, the adapted Charlson Comorbidity Index, the
adapted Diabetes Complication Severity Index, previous events, and number of prescribed chronic medications. For
systolic blood pressure/HbA1C, a double-J/U-curve pattern was detected: HbA1C of 6–6.5% (42-48 mmol/mol) and systolic
blood pressure of 130-140 mmHg (17.3-18.7kPa) were associated with the lowest event risk, values below/above that
range were associated with higher risk. However, this pattern was mainly driven by the death risk and was much less
clearly observed for the macrovascular/microvascular/hospitalization risk and for young/less comorbid patients.
Conclusions: Both blood pressure and HbA1C seem to be very important treatment targets, especially in comorbid old
patients. It is of particular clinical importance that both over- and under-treatment pose a threat to patients with type 2
diabetes mellitus.
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Amongst the most common chronic diseases, type 2 dia-
betes mellitus (T2DM) presents some of the greatest
clinical and health-economic challenges [1]. In addition
to burdens directly associated with this disease, T2DM
patients face an increased frequency of micro- and
macrovascular complications, hospitalisations and in-
creased mortality rates [2-5].
Treatment of T2DM patients should be based on a
broad assessment of patients’ comorbidities, but is, both
in scientific discussion as well as in real life care, still
mainly focused on tight control of diabetes-related sur-
rogate outcomes such as the body mass index (BMI) or
HbA1C [6-12]. However, more recent trials have gener-
ated evidence against strict diabetic control (HbA1C
<6.5%) with particular relevance for the elderly, mostly
comorbid patients as hypoglycemia may represent a par-
ticular threat in this age group [13-17]. In further stud-
ies, a U-/J-shaped impact of HbA1C on macrovascular
event risk was detected indicating that pursuing very
low blood glucose levels may be detrimental, at least for
specific patient groups [18]. Similar patterns have been
reported for another treatment objective, the blood pres-
sure in T2DM patients [19-21]. So, there might be an
over- as well as an under-treating risk of T2DM patients
with regards to more than one treatment objective.
Most of the existing studies, due to their nature and/
or limited sample sizes, do not cover the multimorbid
nature of the real-world treatment of T2DM patients. In
line with that, studies dealing with the assessment of risk
factors possibly associated with diabetes-related events
do not differentiate between different outcome types
(e.g., micro-/macrovascular events or other event types
such as hypoglycaemia) and different patient groups (as
defined by age, gender, comorbidities, and/or T2DM se-
verity) [22]. To address these deficits, some authors de-
veloped comorbidity-based diabetes complication indices
such as the diabetes complications severity index [4] and
the adapted diabetes complications severity index
(aDCSI) [5]. The available publications show these in-
dexes to correlate with diabetes-related event probabil-
ities and/or all-cause hospitalisations. However, these
indexes do not differ between treatment-independent
factors which may be influenced by medical treatment
(such as demographics or comorbidities) to a lesser de-
gree than treatment-dependent risk factors such as
HbA1C, blood pressure, or BMI.
In our study, we had access to a large claims/clinical
dataset that included both information on treatment-
independent and treatment-dependent factors. There-
fore, the aim of this investigation was to analyse which
risk factors predict the real-world risk of a macro-/
microvascular event, T2DM-related hospitalisation, and
all-cause death to happen in T2DM patients. Furthermore,we aimed to investigate whether, with regards to the
treatment-dependent factors, there exists both an under-
as well as an over-treatment risk.
Methods
T2DM sample
We used an anonymised dataset from the German
health fund AOK PLUS which included all T2DM pa-
tients [at least two T2DM diagnoses as outpatient at in-
dependent occasions (ICD E11.-) and/or at least one
inpatient T2DM diagnosis in 2010] who were insured by
this health fund for the entire study period; death during
the observational period was the only exception to the
continuous enrolment requirement. The dataset con-
tained information on the sociodemographic characteris-
tics of the patients, their treatment with outpatient
medications, their outpatient treatment by GP’s and spe-
cialists (diagnoses and frequency of visits), their in-
patient treatment in hospitals, and clinical T2DM-
related data derived from data documented within a dis-
ease management program (DMP) of that health care
fund. All patients in this study had to be registered in
the T2DM-DMP at the beginning of 2011. As part of the
T2DM-DMP, at least once a year and at most quarterly,
HbA1C, BMI, and blood pressure of each enrolled pa-
tient were documented by treating physicians. In sum-
mary, our dataset consisted of T2DM patients for which
claims data in 2010 and both claims and DMP data in
2011 and 2012 were available.
We analysed the frequency of documented T2DM-
related events and/or all-cause death for each study pa-
tient. The time period between 01/04/2011-31/12/2012
(7 quarters) was used as observational period, 2010 and
the first quarter of 2011 were used as reference period.
We included the first quarter of 2011 as reference period
because all DMP-based data were only available in 2011
and starting the observation in the second quarter of
2011 ensured that for most patients at least one refer-
ence data point regarding HbA1C, BMI and blood pres-
sure was available before a potential first event occurred.
Factors describing treatment-independent disease status
of observed T2DM patients
Sociodemographic information and clinical data for each
patient were used to describe the disease/comorbidity
profile of a patient; these data referred to the reference
period. Diabetes-related risk was described based on the
aDCSI [4,5]. The aDCSI describes the frequency/severity
of observed comorbidities identified by ICD codes from
7 complication categories: retinopathy, nephropathy,
neuropathy, cerebrovascular, cardiovascular, peripheral
vascular disease, and metabolic complications; it ranges
from 0 to 13 and was shown to correlate with the num-
ber of all-cause hospitalisations in T2DM patients [4,5]
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bidities which may not be contained in the aDCSI, we
additionally calculated the Charlson Comorbidity index
(CCI; Additional file 2: Table S2) [23]. However, because
we were going to estimate age as separate risk factor, we
excluded age from the CCI (adapted CCI). Because of
the relatively short reference period, some comorbidities
may not have been documented in our dataset by docu-
mented diagnoses which form the basis of the aDCSI
and the CCI. So, we additionally calculated the number
of different prescribed chronic medications in the refer-
ence period (at least two prescriptions per ATC group
(4th level, chemical subgroup [24]) in the reference
period) as proxy for unobserved comorbidities. Finally,
we included in our models occurrence of previous events
in 2010 (hospitalisations because of macro-/microvascular
events or with T2DM as main diagnosis) as variable
describing the morbidity status of the patient.
Factors describing treatment/treatment efficacy of
observed T2DM patients
Treatment and treatment efficacy during the observa-
tional period were described based on data on antidia-
betic/cardiovascular medication treatment and available
HbA1C, BMI, and blood pressure values. All variables
were included as mean, based on the period from 01/01/
2011-31/12/2012. In case that an observed patient expe-
rienced at least one of the diabetes-related events as de-
fined further below, the mean of these variables referred
to the time period until date of this first event.
The number of outpatient treatment visits (GPs and
specialists) was not included as variable describing the
treatment/treatment efficacy during the observational
period because a higher number of physician visits may
indicate a superior treatment, but may also be related to
unobserved events or worsening of the disease status of
the patients so that this variable would be more a
dependent variable than an independent predictor of
diabetes-related events and/or death.
Antidiabetic pharmacotherapy was analysed by deter-
mining the number of active substances (anatomical
therapeutic chemical groups as defined by WHO – ATC
groups [24]) prescribed from 01/01/2011 until 31/12/
2012 per patient or, in the case of events during the ob-
servational period, until an event happened. In order to
describe antidiabetic medication patterns (ATC groups
A10A and A10B), patients were clustered into the fol-
lowing groups: (a) no antidiabetic therapy, (b) metformin
monotherapy, (c) sulfonylureas monotherapy, (d) com-
bination therapy of sulfonylureas/metformin, (e) com-
bination therapy of oral antidiabetics with GLP-1
analogues (f ) mono- or combination therapy of DPP-4
inhibitors, (g) combination therapy of OAD/insulin, (h)
insulin monotherapy, or (i) other combinations. Ifdifferent medications were administered sequentially in
the observational period, these were described as a com-
bination therapy. Additionally, cardiovascular drug
medication therapy was described in the following
groups (k) ACE inhibitors, (l) beta blockers, (m) diuretics,
(n) statins, and (o) antithrombotic drugs (Vitamin K
antagonists and antiplatelets).Observed T2DM-related events
Based on previous publications [3,14,18,25], T2DM-
related outcomes of our study were considered as
follows:
 Macrovascular events
 Hospitalisations with stroke (ICD 10 I60.-/I61.-/
I62.-/I63.-/I64.-)
 Hospitalisations with acute myocardial infarction
(ICD 10 I21.-)
 Hospitalisations with congestive heart failure
(CHF) (ICD 10 I50.-)
 Hospitalisations with coronary revascularizations
(OPS 5-361/5-362/5-363)
 Hospitalisations with percutaneous transluminal
vascular interventions and stent implantations
(OPS 8-836/8-837/8-84)
 Hospitalisations with peripheral vascular disease
(ICD 10 I73.9)
 Hospitalisations with angina pectoris (ICD 10 I20.-)
 Microvascular events
 Hospitalisations with amputation of the lower
extremities (procedural code during
hospitalisation: 5-864/5-865)
 Hospitalisations with vitrectomy (procedural code
during hospitalisation: 5-158/5-159)
 Hospitalisations with chronic kidney disease,
stage 5 (ICD 10 N18.5)
 T2DM-related hospitalisations
 Hospitalisations with T2DM/acute hypoglycaemia
as main diagnosis (ICD 10 E11.-/ E16.0/E16.1/
E16.2)
 Death (any cause)
 Composite outcome consisting of
macrovascular/microvascular events, T2DM-
related hospitalisations, and all-cause death.In order to reliably differentiate acute events from pre-
vious diagnoses/events, in this analysis ICD diagnoses/
procedures documented were only considered as an
event if they were either associated with acute hospitali-
sations as main diagnosis or death of the patient. Main
outcome used in this study was a composite outcome
(occurrence of any of the above events), in additional
analyses the four event types were analysed separately.
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The event frequency was reported as event-specific
event probability per patient year in 01/04/2011-31/
12/2012. Furthermore, percentage of event-free pa-
tients over time was depicted by using Kaplan Meier
(KM) curves for the whole sample as well as for differ-
ent patient groups as defined by age, gender, or co-
morbidity status; significance of differences between
event rates was tested by using log-rank tests.
In order to analyse independent factors associated
with the observed event risk, we did 11 multivariable
Cox regression analyses; Figure 1 describes these
models. Factors associated with the time until event in
the observational period (01/04/2011-31/12/2012)
were analysed using backward elimination method-
ology. All factors not reaching statistical significance
(p < 0.1) were excluded in a stepwise procedure. Fi-
nally, factors reaching a p < 0.05 were interpreted as
statistically significant. In the models, the following
covariates were initially included: as treatment-
independent factors age, gender, aDCSI, adjusted CCI
as defined above, number of all prescribed chronic
medications, occurrence of a previous macro-/micro-
vascular event or a hospitalisation with T2DM as main
diagnosis; as treatment-dependent factors (all related
to 01/01/2011-31/12/2012 or until time of event,Analysis of event-risk for specific outcome
categories: all T2DM patients (n=229,042)
1: Main analysis: all T2DM patients
(n = 229,042)
Dependent variable: time until all-

























2: Analysis of macrovascular
outcome risk
Dependent variable: time until
macrovascular event in 
01/04/2011-31/12/2012
3: Analysis of microvascular
outcome risk
Dependent variable: time until
microvascular event in 
01/04/2011-31/12/2012
4: Analysis of risk of a T2DM-
related hospitalization
Dependent variable: time until
hospitalization with T2DM as








5: Analysis of all-cause death risk
Dependent variable: time until
death in 01/04/2011-31/12/2012
Figure 1 Overview of different Cox regression models. The figure desc
assess the association between chosen independent risk factors and observwhatever came first): antidiabetic and cardiovascular
medication therapy as defined above, mean HbA1c,
mean BMI, and mean systolic blood pressure. Model 1
analysed all observed T2DM patients estimating time
until all-cause event (composite outcome as defined
above) as dependent variable. The models 2–5 analysed
time until first macrovascular event (model 2), micro-
vascular event (model 3), hospitalisation with T2DM as
main diagnosis (model 4), and all-cause death (model
5) separately. In models 6–11, separate patient sub-
groups as defined by gender and age/comorbidity sta-
tus were analysed using time until all-cause event
(composite outcome) as dependent variable in each of
the models. In terms of age/comorbidity status, pa-
tients with an age of < 72 years at the beginning of the
observational period and an adapted CCI < 4 were
interpreted as young/less comorbid patients whereas
all other patients were grouped into the older/more
comorbid patient subgroups. All reported p-values
were two-sided, and 95% CIs were calculated for haz-
ard ratios (HRs). All descriptive evaluations were done
with Microsoft SQL Server 2008 and Microsoft Excel
2010. All other statistical analyses were done with
SPSS 17.0. The study was approved by the independent
ethical review board of the Thuringia State Medical
Association (Germany).Analysis of all-cause event risk (composite outcome) for specific patient groups
nalysis of male patients
(n = 103,500)
ndent variable: time until all-
use event in 01/04/2011-
31/12/2012
nalysis of female patients
(n = 125,542)
ndent variable: time until all-
use event in 01/04/2011-
31/12/2012
8: Analysis of old/comorbid male patients
(n = 63,815)
Dependent variable: time until all-cause event in 
01/04/2011-31/12/2012
9: Analysis of young/less comorbid male 
patients (n=39,685)
Dependent variable: time until all-cause event in 
01/04/2011-31/12/2012
10: Analysis of old/comorbid female patients
(n = 88,253)
Dependent variable: time until all-cause event in 
01/04/2011-31/12/2012
11: Analysis of young/less comorbid female
patients (n = 37,289)
Dependent variable: time until all-cause event in 
01/04/2011-31/12/2012
ribes the 11 different multivariable Cox regression analyses used to
ed event risk.
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T2DM sample
In our sample, a total of 229,042 T2DM patients were
identified (Table 1). This sample (54.8% female) was
characterized by a mean age of 70.2 years and a high
number of comorbidities per patient (mean CCI 6.03;
mean CCI without age factor: 3.65); the five most com-
mon comorbidities were hypertension (86.9% of the pa-
tients), lipid metabolism disorders (50.7%), disorders ofTable 1 Sociodemographic characteristics of observed type 2




Baseline characteristics (reference period)
Mean age in years (SD) 70.23
Female gender (%) 125,542
Mean number of long-term prescribed medications
(SD) (at least two prescriptions per ATC code - 4th
level)
6.10
Mean CCI (SD) 6.03
Mean adapted CCI without age factor (SD) 3.65
Mean aDSCI (SD) 1.92
Number of patients (%) with at least one previous
diabetes-related event
13,967
5 most common comorbidities;
Number of patients (%) with
Hypertension (ICD-10: I10) 199,079
Disorders of lipoprotein metabolism (ICD-10: E78) 116,230
Disorders of refraction and accommodation (ICD-10:
H52)
103,471
Dorsalgia (ICD-10: M54) 82,932
Chronic ischaemic heart disease (ICD-10: I25) 79,482
Treatment-dependent variables (based on 01/01/2011
until 31/12/2012 or date of first event)
Mean HbA1C in % (SD) 7.00
Number of patients (%) with mean HbA1C
<6.0% / <42 mmol/mol
25,445
Number of patients (%) with mean HbA1C
<7.5% / <58 mmol/mol
172,373
Number of patients (%) with mean HbA1C
≥9.0% / ≥75 mmol/mol
10,308
Mean BMI (SD) 30.46
Number of patients (%) with BMI >30 110,014
Mean systolic blood pressure in mmHg (SD) 135.56
Number of patients (%) with systolic blood pressure
>130 mmHg / >17.3kPa
151,806
Mean diastolic blood pressure in mmHg (SD) 78.75
Number of patients (%) with diastolic blood pressure
>80 mmHg / >10.7kPa
78,511
Legend: The table lists sociodemographic characteristics for two different samples: a) typ
(study sample) and b) study sample patients which experienced a diabetes-related eventaccommodation/refraction (45.2%), dorsalgia (36.2%)
and chronic ischaemic heart disease (34.7%).
Treatment of T2DM patients
A total of 66.3% of our T2DM study sample had a mean
systolic blood pressure of > 130 mmHg (mean:
135.56 mmHg). 34.3% of the observed patients had a
diastolic blood pressure of > 80 mmHg (mean
78.75 mmHg). 48.0% of the observed patients could bediabetes mellitus-samples
t patients with complete
ion (study sample)
Study sample patients which
experienced at least one diabetes-related
























e 2 diabetes mellitus-prevalent (2010) patients with complete DMP-documentation
during the observational period.
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in the sample was 7.00%; 11.1% of the observed patients
had a mean HbA1C < 6.0%, 75.3% of the patients had a
mean HbA1C <7.5% and 4.5% of the patients in the study
sample had a mean HbA1C ≥ 9.0% (Table 1).
Diabetes-related events
The mean observational period per patient from 01/04/
2011 until 31/12/2012 or until first observed all-cause
event was 581.9 days (SD: 148.4). 39,589 patients of the
study sample (17.3%) were affected by at least one T2DM-
related event in this period. 22,232 patients (9.7%; 82.7
events per 1,000 patient years) were affected by at least
one macrovascular event during the observational period,
3,249 patients (1.4%; 10.8 events per 1,000 patient years)
suffered from at least one microvascular event, 8,717
patients (3.8%; 28.4 events per 1,000 patient years) experi-
enced at least one hospitalisation with T2DM as main
diagnosis, and 15,802 patients (6.9%; 40.7 deaths per 1,000






< 72 years 602.23
< 0.001
>= 72 years 562.40
Test of equality of survival distributions for 
the different levels of age.
88.6 %
77.1 %
Figure 2 Kaplan-Meier curves for percentage of event-free patients d
regarding the percentage of event-free patients (all-cause event; composite
as defined by age, gender, or comorbidity status.Figure 2 depicts the percentage of event-free patients over
time using KM curves. Obviously, event risk was positively
associated with older age, male gender, and higher CCI.
Factors associated with event risk (model 1)
Figure 3 shows the results of our multivariable analysis
regarding factors influencing time until an all-cause
event (composite outcome). All included treatment-
independent factors did influence the T2DM-related
event risk. In our sample, women faced an under-
average event risk (HR 0.711) whereas older patients
faced a higher event risk (HR 1.032 related to each year
of age). The adjusted CCI (HR 1.059 related to values
between 1–20), the aDCSI (HR 1.070 related to values
between 0–12), the number of prescribed chronic medi-
cations (HR 1.072), and any previous event in 2010 (HR
1.508) also positively influenced the event risk.
The mean BMI of the patients was a treatment-
dependent factor that was not associated with the










Test of equality of survival distributions for 






CCI <= 3 607.52
< 0.001
CCI > 3 548.63
Test of equality of survival distributions for 




uring observational period. The figure shows Kaplan-Meier curves
outcome) for the whole sample as well as for different patient groups
* p < 0.001; ** p < 0.005; *** p < 0.010; **** p < 0.050; ***** p < 0.100
- Model 1 -
Whole study sample
Hazard ratio (95%-CI):
Time until all-cause event
Figure 3 Factors associated with event risk (model 1). The figure shows the results of the multivariable analysis with regards to independent
factors influencing time until an all-cause event (composite outcome) in the whole study sample.
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- Model 2 -
Hazard ratio (95%-CI): 
time until macrovascular event
- Model 3 -
Hazard ratio (95%-CI): 
time until microvascular event
- Model 4 -
Hazard ratio (95%-CI): 
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- Model 5 -
Hazard ratio (95%-CI): 
time until all-cause death
* p < 0.001; ** p < 0.005; *** p < 0.010; **** p < 0.050; ***** p < 0.100
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Figure 4 Factors associated with risk of different events (models 2–5). The figure compares the results of the multivariable analyses with re ds to chosen independent factors being
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methodology. Related to cardiovascular drug therapy,
some medications (diuretics: HR 1.276, antithrombotic
drugs: HR 1.085) were associated with a higher event
risk, others (ACE inhibitors: OR 0.782, statins: HR 0.737,
beta blockers HR 0.954) were associated with a lower
event risk. In terms of antidiabetic medication therapy,
SU monotherapy was excluded from the model because
of an insignificant association with event risk. All other
observed therapy options except of insulin monotherapy
(HR 1.181) were associated with a lower event risk
(reference group: no antidiabetic medication).
With regards to systolic blood pressure, we could detect
a U-/J-shaped influence on diabetes-related event risk.
Using a mean systolic blood pressure of <100 mmHg as ref-
erence group, a systolic blood pressure of 130–140 mmHg
(HR 0.393) was associated with the lowest event risk; values
below/above that “optimal” systolic blood pressure were as-
sociated with higher event risks.
The HbA1C as most prominent treatment-dependent
risk factor in scientific diabetologic discussion clearly in-
fluenced the event risk. We could detect a U-/J-shaped
influence of the HbA1C values on diabetes-related event
risk. Using a mean HbA1C value of <5% as reference
group, a mean HbA1C of 6.0-6.5 was associated with the
lowest event risk (HR 0.466). Lower HbA1C values (5.0-
5.5: HR 0.662; 5.5-6.0 HR 0.502) seemed to be associated
with higher event risks, whereas higher HbA1C values
were also associated with a higher event risk; the re-
spective hazard ratios for the HbA1C classes were: 0.503
(6.5-7.0), 0.533 (7.0-7.5), 0.588 (7.5-8.0), 0.659 (8.0-8.5),
0.771 (8.5-9.0), 0.892 (9.0-9.5; not significant), 0.931
(9.5-10.0; not significant), and 1.411 (>10.0).
Factors associated with specific outcomes risk (models 2–5)
Figure 4 shows results of the multivariable Cox regres-
sion estimates with regards to macrovascular event risk
(model 2), microvascular event risk (model 3), T2DM-
related hospitalisation risk (model 4), and all-cause mor-
tality risk (model 5). As in model 1, female gender, older
age (exception: microvascular events), a higher aDCSI, a
high number of prescribed medications and any ob-
served previous events are positively associated with the
event risk. However, a higher CCI was only associated
with a higher macrovascular event and death risk; it did
not influence the T2DM-related hospitalisation risk and
even moderately decreased the microvascular event risk
(HR 0.959).
As described above, BMI as independent factor was
excluded from model 1 because of its insignificance.
However, a higher BMI was associated with a higher
macrovascular event risk (HR 1.008) and a lower death
risk (HR 0.980). In terms of cardiovascular medication,
the results of model 1 were mainly confirmed in models2–5. Only results related to beta blockers and anti-
thrombotic drugs differed between the models. Similarly,
the results with regards to antidiabetic medication in
model 1 could be confirmed in the models 2, 3, and 5;
in model 3 (microvascular events), some agents were ex-
cluded because of an insignificant influence. However,
whereas most of the antidiabetic agents were associated
with lower macrovascular/microvascular event and
lower death risk, all antidiabetic agents were positively
associated with the risk to experience a hospitalisation
with T2DM as main diagnosis (model 4). Highest hazard
ratios could be detected for insulin monotherapy (HR
4.228), OAD/insulin combination therapy (HR 3.162),
sulfonylurea/metformin combination therapy (2.950),
and sulfonylurea monotherapy (HR 2.858). 21.2% of the
T2DM-related hospitalisations were due to a hypoglycaemia
(main diagnosis).
With regards to systolic blood pressure, the observed
U/J-curve pattern found in model 1 could only be con-
firmed for the macrovascular event risk and, even more
pronounced, for the mortality risk. Here, a blood pres-
sure of 140–150 mmHg was associated with the lowest
death risk (HR 0.262; reference: systolic blood pressure
< 100 mmHg), whereas lower and higher blood pressure
values were associated with a higher event risk.
With regards to the influence of HbA1C on the event
risk, the results also depended on the observed outcome
category. The U/J-curve pattern which was found in
model 1 could be confirmed in model 5 (death risk).
However, in model 2 (macrovascular event risk), only a
very high HbA1C > 10% was associated with an elevated
event risk. With regards to microvascular complications,
a HbA1C value between 5.5-8.0 could be shown as being
risk-protective. For T2DM-related hospitalisations, a
HbA1C > 8.5 was associated with a higher event risk.
Factors associated with all-cause event risk in specific pa-
tient subsamples (models 6–11)
Figure 5 shows the results of the multivariable Cox re-
gression estimates with regards to the composite out-
come (all-cause events) for 6 patient subgroups: all
males (model 6), all females (model 7), old/more comor-
bid males (model 8), young/less comorbid males (model
9), old/more comorbid females (model 10), and young/less
comorbid females (model 11). With regards to sociodemo-
graphics/comorbidities, the previously described results
could be confirmed across all subgroups. The only specific
is the more pronounced influence of previous events in
the young/less comorbid patient subgroups. Again, results
for BMI as independent risk factor were inconclusive.
Association of certain prescribed cardiovascular drugs
with event risk was similar in all models according to
the results in model 1. Also, the risk profile associated
with specific antidiabetic medication patterns was
0.000 1.000 2.000 3.000 0.000 1.000 2.000 3.000 0.000 1.000 2.000 3.000 0.000 1.000 2.000 3.000 0.000 1.0 2.000 3.000 0.000 1.000 2.000 3.000
- Model 6 -
Males
Hazard ratio (95%-CI):
Time until all-cause event
1.043 (1.041 - 1.044)*
1.055 (1.047 - 1.063)*
1.067 (1.057 - 1.078)*
1.076 (1.071 - 1.082)*
1.433 (1.369 - 1.500)*
1.003 (1.000  - 1.005)****
0.746 (0.665 - 0.837)*
0.450 (0.402 - 0.502)*
0.369 (0.330 - 0.412)*
0.373 (0.332 - 0.418)*
0.398 (0.352 - 0.450)*
0.506 (0.440 - 0.583)*
0.663 (0.567 - 0.775)*
0.556 (0.419 - 0.736)*
0.423 (0.325 - 0.550)*
0.395 (0.304 - 0.514)*
0.432 (0.333 - 0.562)*
0.466 (0.358 - 0.606)*
0.504 (0.387 - 0.657)*
0.569 (0.436 - 0.742)*
0.635 (0.485 - 0.830)**
0.748 (0.569 - 0.983)****
0.751 (0.568 - 0.994)****
1.267 (0.965 - 1.662)*****
0.786 (0.758 - 0.815)*
0.961 (0.932 - 0.991)****
1.247 (1.205 - 1.290)*
0.731 (0.710 - 0.754)*
1.087 (1.054 - 1.121)*
0.803 (0.760 - 0.849)*
excluded
0.907 (0.848 - 0.971)***
0.779 (0.621 - 0.978)****
0.608 (0.550 - 0.674)*
0.932 (0.886 - 0.981)***
1.257 (1.200 - 1.317)*
0.856 (0.801 - 0.915)*
1.024 (1.022 - 1.025)*
1.066 (1.058 - 1.073)*
1.072 (1.062 - 1.083)*
1.069 (1.064 - 1.075)*
1.562 (1.499 - 1.628)*
excluded
0.751 (0.677 - 0.834)*
0.487 (0.441 - 0.538)*
0.414 (0.375 - 0.458)*
0.422 (0.380 - 0.468)*
0.474 (0.423 - 0.531)*
0.547 (0.476 - 0.628)*
0.798 (0.682 - 0.935)***
0.760 (0.578 - 1.001)*****
0.583 (0.449 - 0.757)*
0.543 (0.419 - 0.704)*
0.579 (0.446 - 0.750)*
0.604 (0.465 - 0.784)*
0.676 (0.520 - 0.879)**
0.754 (0.579 - 0.981)****
0.924 (0.708 - 1.206)
1.041 (0.793 - 1.367)
1.140 (0.863 - 1.505)
1.553 (1.186 - 2.034)**
0.774 (0.746 - 0.803)*
0.949 (0.920 - 0.979)**
1.289 (1.246 - 1.332)*
0.751 (0.729 - 0.774)*
1.088 (1.053 - 1.124)*
0.802 (0.760 - 0.846)*
Excluded
0.833 (0.779 - 0.891)*
0.654 (0.541 - 0.790)*
0.560 (0.508 - 0.618)*
0.807 (0.767 - 0.850)*
1.087 (1.037 - 1.141)**
0.803 (0.756 - 0.854)*
1.107 (1.097 - 1.117)*
1.077 (1.072 - 1.082)*
1.541 (1.477 - 1.608)*
0.989 (0.986 - 0.993)*
0.772 (0.693 - 0.860)*
0.496 (0.447 - 0.550)*
0.419 (0.377 - 0.464)*
0.418 (0.375 - 0.465)*
0.471 (0.417 - 0.531)*
0.554 (0.476 - 0.645)*
0.758 (0.635 - 0.904)**
0.757 (0.566 - 1.014)*****
0.604 (0.458 - 0.796)*
0.567 (0.431 - 0.747)*
0.609 (0.463 - 0.802)*
0.642 (0.488 - 0.846)**
0.703 (0.533 - 0.927)****
0.767 (0.580 - 1.013)*****
0.939 (0.709 - 1.244)
1.030 (0.772 - 1.375)
1.035 (0.769 - 1.392)
1.395 (1.046 - 1.860)****
0.738 (0.708 - 0.769)*
0.894 (0.864 - 0.925)*
1.312 (1.265 - 1.360)*
0.711 (0.687 - 0.735)*
1.035 (0.999 - 1.071)*****
0.739 (0.699 - 0.782)*
excluded
0.773 (0.722 - 0.829)*
0.549 (0.422 - 0.713)*
0.514 (0.461 - 0.573)*
0.697 (0.667 - 0.728)*
excluded
0.767 (0.721 - 0.817)*
1.210 (1.175 - 1.248)*
1.064 (1.049 - 1.079)*
1.968 (1.710 - 2.264)*
excluded
1.007 (0.645 - 1.572)
0.703 (0.455 - 1.084)
0.599 (0.388 - 0.922)****
0.643 (0.416 - 0.995)****
0.678 (0.433 - 1.061)*****
0.733 (0.456 - 1.179)
1.251 (0.767 - 2.042)
0.787 (0.341 - 1.814)
0.561 (0.250 - 1.260)
0.555 (0.248 - 1.241)
0.602 (0.269 - 1.346)
0.608 (0.271 - 1.361)
0.748 (0.334 - 1.678)
0.914 (0.407 - 2.055)
1.031 (0.456 - 2.330)
1.209 (0.533 - 2.745)
1.616 (0.707 - 3.694)
2.048 (0.907 - 4.622)*****
0.873 (0.800 - 0.953)**
1.093 (1.015 - 1.177)****
1.416 (1.308 - 1.534)*
0.819 (0.761 - 0.881)*
1.413 (1.305 - 1.531)*
excluded
1.409 (1.161 - 1.709)**
excluded
0.683 (0.524 - 0.891)***
0.659 (0.546 - 0.795)*
excluded
1.282 (1.162 - 1.415)*
0.876 (0.786 - 0.975)****
1.112 (1.103 - 1.122)*
1.072 (1.067 - 1.077)*
1.404 (1.340 - 1.472)*
0.984 (0.981 - 0.987)*
0.811 (0.720 - 0.915)**
0.482 (0.429 - 0.541)*
0.392 (0.349 - 0.441)*
0.392 (0.348 - 0.442)*
0.427 (0.375 - 0.485)*
0.511 (0.439 - 0.594)*
0.698 (0.592 - 0.823)*
0.617 (0.462 - 0.824)**
0.490 (0.374 - 0.643)*
0.455 (0.348 - 0.596)*
0.504 (0.385 - 0.660)*
0.528 (0.403 - 0.692)*
0.559 (0.426 - 0.734)*
0.637 (0.485 - 0.837)**
0.686 (0.521 - 0.905)***
0.776 (0.585 - 1.029)*****
0.769 (0.576 - 1.028)*****
1.120 (0.845 - 1.486)-
0.787 (0.757 - 0.818)*
0.941 (0.911 - 0.972)*
1.375 (1.328 - 1.425)*
0.673 (0.653 - 0.695)*
1.079 (1.045 - 1.114)*
0.754 (0.711 - 0.799)*
excluded
0.843 (0.784 - 0.905)*
0.553 (0.403 - 0.759)*
0.554 (0.496 - 0.619)*
0.833 (0.789 - 0.879)*
1.219 (1.161 - 1.279)*
0.784 (0.730 - 0.842)*
1.153 (1.107 - 1.200)*
1.097 (1.079 - 1.116)*
2.873 (2.364 - 3.492)*
excluded
0.529 (0.354 - 0.789)**
0.346 (0.237 - 0.504)*
0.295 (0.203 - 0.429)*
0.338 (0.231 - 0.496)*
0.294 (0.195 - 0.444)*
0.512 (0.331 - 0.792)**
0.509 (0.311 - 0.831)***
0.533 (0.158 - 1.793)
0.385 (0.121 - 1.221)
0.488 (0.155 - 1.535)
0.518 (0.165 - 1.626)
0.680 (0.216 - 2.138)
0.858 (0.272 - 2.701)
0.809 (0.256 - 2.556)
1.030 (0.325 - 3.265)
1.400 (0.439 - 4.468)
1.392 (0.432 - 4.480)
2.751 (0.870 - 8.696)*****
0.870 (0.779 - 0.972)****
excluded
1.325 (1.197 - 1.466)*
0.778 (0.707 - 0.857)*
1.379 (1.240 - 1.533)*
0.767 (0.659 - 0.893)*
excluded
excluded
0.634 (0.453 - 0.886)***
0.567 (0.440 - 0.732)*
0.861 (0.740 - 1.001)*****
1.371 (1.160 - 1.619)*
0.797 (0.670 - 0.947)****
- Model 7 -
Females
Hazard ratio (95%-CI):
Time until all-cause event
- Model 8 -
Old/comorbid males
Hazard ratio (95%-CI):
Time until all-cause event
- Model 9 -
Young/less comorbid males
Hazard ratio (95%-CI):




Time til all-cause event
- Model 11 -
Young/less comorbid females
Hazard ratio (95%-CI):
Time until all-cause event
* p < 0.001; ** p < 0.005; *** p < 0.010; **** p < 0.050; ***** p < 0.100
Figure 5 Factors associated with event risk in different subsample (models 6–11). The figure compares the results of the multivariable analys with regards to factors being possibly associated
with time until an all-cause event (composite outcome) in the subsamples of male patients (model 6) and female patients (model 7) as well as in the up of old/comorbid male/female patients (models
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ation between sulfonylurea monotherapy and all-cause
event risk could only be shown in the subsample of
young/less comorbid male patients.
The observed U/J curve pattern for the association be-
tween systolic blood pressure and all-cause event risk
could be confirmed for both male and female patients.
However, it seems to be more pronounced in the female
patients and old/comorbid patients subsamples. Lowest
event risk was associated with a systolic blood pressure
(reference group: <100 mmHg) of 130–140 mmHG or
140-150mmHG (old/more comorbid patients).
The observed U/J curve pattern for the association be-
tween HbA1C and all-cause event risk could be observed
across male and female patients (models 6, 7). The opti-
mal HbA1C of 6.0-6.5 (reference: <5.0) seemed to be
more risk-protective for female patients (HR 0.395) than
for male patients (HR 0.543). Results of models 9 and 11
show that mean HbA1C was not systematically associ-
ated with all-cause event risk in young/less comorbid pa-
tients. The observed relationship between HbA1C and
all-cause event risk could only be observed in the old/
more comorbid patient subsamples (both males/females:
models 8 and 10). In these models, a HbA1C of 6.0-6.5
was associated with the lowest event risk.
Conclusions
Study objectives and main results
Based on a German claims dataset, we aimed to identify
both treatment-independent and treatment-dependent
factors that are associated with the T2DM-related event
risk. The main strength of our analysis lies in the avail-
ability of a very large, data-rich dataset.
Our analysis confirms the influence of age, gender, and
number of comorbidities as measured by the adjusted
CCI, number of prescribed medications, the aDCSI, and
previous events on the event risk as earlier studies did
[4,5,25]. In our study, certain medication groups both in
terms of cardiovascular and antidiabetic medication were
associated with higher/lower event risk rates as well. Be-
cause most of these drugs are not substitutes for each
other, we do believe that these different event rates are
more an indication of existing/undetected comorbidities
of patients or T2DM disease severity/length than an in-
dication that treatment of these patients should switch
to those drugs that are associated with lower event rates.
This is particularly conceivable as a true placebo-control
is necessary to validate drug efficacy, but not available
here.
Nevertheless, the lower risk of GLP-1, DPP4 or
metformin-based treatments versus sulfonylurea and
insulin-containing regimens may underpin the advantage
of lower rates of hypoglycemia [26] with former ones
leading to endpoint-relevant differences in other studiesas well [27]. Hypoglycemia is the major downside of sul-
fonylurea or insulin-based regimens [28] and is one of
the major causes of hospitalisations with T2DM as main
diagnosis in our study.
In our multivariate statistical analysis, the mean BMI
did not exert an independent influence on T2DM-
related event rates. Here, our study confirms earlier
studies that found it difficult to identify a closely, statisti-
cally identifiable relationship between weight/BMI and
cardiovascular event rates [28].
Our multivariate statistical analysis shows that treating
physicians face a “double-U-/J-curve”-pattern in treating
multimorbid T2DM patients. First, we could detect this
U-/J-curve shaped influence of systolic blood pressure
on diabetic-related events with a systolic blood pressure
of 130–140 mmHg as being the optimal range. However,
this result is mainly driven by the macrovascular event
and death risk. This observation is in line with major
T2DM clinical trials such as the UKPDS which clearly
showed an even larger endpoint effect of blood pressure
than glucose lowering [29]. Also, the observed U-/J-
curve pattern was already shown in some studies
[19-21,30].
Despite controlling for many covariates, our results
support the conclusion that HbA1C remains an import-
ant treatment-dependent factor associated with the
T2DM-related event risk, even if the analysis controls
for different antidiabetic medication therapies. In this,
we confirm the results of earlier real life studies
[13,14,18,31]. We also confirm that a U-/J-shaped influ-
ence of HbA1C on T2DM-related event risk may exist as
shown by more recent studies [13,18]. Our data indicate
that a HbA1C of 6.0-6.5% may be associated with the
lowest T2DM-related event rate and a HbA1C < 6.0%
may be associated with higher event rates. This confirms
the recently found relationship between hypoglycaemic
events and cardiovascular events [32]. However, that
does not mean that reduction of HbA1C to a goal of 6.0-
6.5% in all (especially older) patients may automatically
be associated with an overall reduction of T2DM-related
events/mortality as the well-known ACCORD study has
shown [33,34]. Furthermore, HbA1C variability has found
to be an independent predictor for development of car-
diovascular diseases [35].
In terms of specific outcomes, interestingly, our
models 2–5 showed that the observed U/J-curve like in-
fluence of HbA1C on event risk only exists for the death
risk (model 5). For macro-/microvascular events and
T2DM-related hospitalisations, we observed the risk-
protective nature of low/moderate HbA1C values, but no
clear U/J-curve pattern could be shown. Furthermore,
models 6–11 demonstrated that HbA1C is hardly related
to any outcome risk in young/less comorbid patients.
Obviously, death risk is the mainly driver of the close
Wilke et al. Cardiovascular Diabetology  (2015) 14:14 Page 12 of 14relationship between HbA1C and event risk; mortality
risk is generally low in the younger/less comorbid pa-
tient groups. Whether mortality risk is, on the other
hand, related to macrovascuar causes is not known be-
cause no death cause has been documented in the
database.
On the other hand, in old/more comorbid patients, influ-
ence of HbA1C on overall event risk following a U-/J-curve
could be assessed. Here, we cannot confirm the general
conclusion that more comorbid T2DM patients may not
benefit from low blood glucose values [25,36]; the risk-
minimizing HbA1C was a mean value of 6.0-6.5. So, our
results support the general conclusion that HbA1C control
should be an important part of a general multidisciplinary
risk assessment/management effort in an effective T2DM
treatment [37].Limitations
We acknowledge limitations of our analysis. First, due to
the limitations of our dataset we could not include all vari-
ables of interest. Patient characteristics not associated with
specific diagnoses and/or prescription patterns like smok-
ing/non-smoking behavior, preclinical atherosclerosis [38],
specific GFR values [39] or level of physical activity [40]
were not visible. As treatment-dependent variable, most
importantly, total or LDL-cholesterol values that have
been found to be an independent cardiovascular risk fac-
tor in other T2DM studies [18,41] were not available.
Nevertheless, in our multivariable analysis, statins have
been found to be associated with a lower diabetes-related
event risk which is in line with clinical findings [42].
Second, less acute events treated in the outpatient sec-
tor were not included in our study because differenti-
ation of acute events and earlier events based on
outpatient diagnoses only was not possible based on our
database. Furthermore, it cannot be ruled out completely
that, despite using events related to acute hospitalisations,
some of the identified hospitalisations were directly associ-
ated with previous events.
Third, despite the fact that we analyzed a very large
dataset we covered only a short observational period of
21 months. Further research is needed to describe the
more long-term consequences of the analyzed risk fac-
tors of T2DM-related events, especially in younger/less
comorbid patients with generally lower event rates.
Fourth, our sample consisted of comparatively old/co-
morbid T2DM patients which led to high average event
rates. This is due to the nature of the insured persons of
the health care fund AOK Plus which provided the data.
So, T2DM patients with higher comorbidity levels are
over-represented in our study. Given this, the range for
an optimal HbA1C between 6.0 and 6.5 appears to be ra-
ther low given those recommendations cited above forelderly and multimorbid patients. However, though
representing a relatively old sample, very compromised
elderly may not have been included as they did not par-
ticipate in DMPs and/or were mainly residing in nursing
homes. In addition, sicker patients may not have been
treated against T2DM at the same intensity as fitter eld-
erly as risk aversion and, thus, reduced treatment inten-
sity had been suggested for those frail patients by former
studies. Furthermore, negative experiences (hypoglycemia)
prior to the observational period could have resulted in a
pre-selection of fitter elderly which were assumed to be
less threatened by hypoglycemia than the frail elderly, and
a selection of elderly patients with fewer hypoglycemic
complications at low HbA1C levels. Despite statistical
control, these biases may have resulted in falsely linking
tighter T2DM control with favourable outcomes in the
elderly. These points could explain the apparent discrep-
ancy bearing in mind that this is no long-term interven-
tional study. In addition, the confidence intervals for the
optimal ranges for HbA1C and systolic blood pressure have
not been statistically determined, but result from graphical
estimation; the true ranges may thus be different from
those estimates.
Fifth, we acknowledge that some of the observed/ana-
lyzed risk factors may be correlated to each other. This
is certainly true for the age, CCI, number of chronic
medications and the aDCSI. On the other hand, our ana-
lysis aimed to cover comorbid conditions possibly asso-
ciated with T2DM-related risks as closely and as
completely as possible in order to be able to describe the
remaining effect of treatment-dependent factors on
event risk in the most meaningful way.
Sixth, due to our large sample size, some independent
variables may exert a statistical influence but, due to low
odds ratios, not in a clinically meaningful way. So, in de-
riving conclusions, we evaluated both statistical signifi-
cance and clinical relevance of results.
Conclusions and implications for practice
Our study confirms that comorbidities play an important
role for the prognosis of the micro-/macrovascular event/
hospitalisation/death risk in T2DM patients. Both blood
pressure and HbA1C seem to be very important targets. It
is of particular clinical importance that both over- and
under-treatment pose a threat to T2DM patients because
both parameters influence diabetes-related event risk and,
mainly, mortality risk in a U-/J-shaped pattern.
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